IL247653B - Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole - Google Patents

Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole

Info

Publication number
IL247653B
IL247653B IL247653A IL24765316A IL247653B IL 247653 B IL247653 B IL 247653B IL 247653 A IL247653 A IL 247653A IL 24765316 A IL24765316 A IL 24765316A IL 247653 B IL247653 B IL 247653B
Authority
IL
Israel
Prior art keywords
salts
pharmaceutical compositions
benzoic acid
oxadiazole benzoic
oxadiazole
Prior art date
Application number
IL247653A
Other languages
English (en)
Hebrew (he)
Other versions
IL247653A0 (en
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of IL247653A0 publication Critical patent/IL247653A0/en
Publication of IL247653B publication Critical patent/IL247653B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
IL247653A 2014-03-06 2016-09-05 Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole IL247653B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949052P 2014-03-06 2014-03-06
US201462009111P 2014-06-06 2014-06-06
PCT/US2015/018889 WO2015134711A1 (en) 2014-03-06 2015-03-05 Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Publications (2)

Publication Number Publication Date
IL247653A0 IL247653A0 (en) 2016-11-30
IL247653B true IL247653B (en) 2022-04-01

Family

ID=54055864

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247653A IL247653B (en) 2014-03-06 2016-09-05 Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole

Country Status (10)

Country Link
US (3) US9873677B2 (enExample)
EP (1) EP3113619A4 (enExample)
JP (3) JP6946001B2 (enExample)
KR (2) KR102497273B1 (enExample)
CN (3) CN106455571A (enExample)
CA (2) CA3174516A1 (enExample)
EA (1) EA032779B1 (enExample)
IL (1) IL247653B (enExample)
TW (2) TWI636978B (enExample)
WO (1) WO2015134711A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
SG185979A1 (en) * 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
CN106455571A (zh) * 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
TW201729807A (zh) 2015-10-30 2017-09-01 Ｐｔｃ治療公司 用於治療癲癇的方法
PT3377476T (pt) * 2015-11-16 2022-12-29 Ptc Therapeutics Inc Análogos enriquecidos com isótopo de hidrogénio de compostos de ácido 1,2,4-oxadiazole benzoico, composições e suas utilizações
JP2019505579A (ja) 2015-12-23 2019-02-28 ムーンショット ファーマ エルエルシー 免疫応答を誘導するための方法
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC CANCER TREATMENT METHODS USING COMPOSITIONS INCLUDING AMLEXANOX AND IMMUNOMODULATORS
US11203578B2 (en) 2017-11-23 2021-12-21 Universita'degli Studi Dipalermo Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
CN109678715B (zh) * 2018-11-28 2019-11-12 中国药科大学 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
US10637694B1 (en) 2018-12-21 2020-04-28 At&T Intellectual Property I, L.P. Reduction and/or mitigation of spatial emissions in multi-antenna wireless communication systems for advanced networks
EA202192767A1 (ru) 2019-04-10 2021-12-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов
EP4259097A1 (en) * 2020-12-14 2023-10-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Ataluren eye drop formulation
WO2023205175A1 (en) * 2022-04-18 2023-10-26 Vanderbilt University Polysulfide microparticles and uses thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (enExample) 1962-04-17
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
TR199800414T1 (xx) 1995-09-07 1998-05-21 Novartis Ag De�i�tirilmi� fosfinik bile�ikler ve ila� olarak kullan�m�.
WO1997041105A1 (en) 1996-04-26 1997-11-06 Nippon Soda Co., Ltd. Novel heterocycle-substituted benzene derivatives and herbicides
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP0906310A4 (en) 1996-06-07 1999-09-01 Merck & Co Inc OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
AU9647998A (en) 1997-10-27 1999-05-17 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
CA2329712A1 (en) 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
DE69914931T2 (de) 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
HK1043536A1 (zh) 1998-12-23 2002-09-20 Smithkline Beecham Corporation 蛋白酶抑制剂
WO2000058278A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives d'acides amines $g(b)
WO2000058280A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
WO2000058304A1 (en) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
CN1356977A (zh) 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2003528107A (ja) 2000-03-22 2003-09-24 メルク フロスト カナダ アンド カンパニー Ｐｔｐ−１ｂ阻害薬としての硫黄置換アリールジフルオロメチルホスホン酸類
WO2001083464A1 (en) 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
AR033525A1 (es) 2000-05-22 2003-12-26 Aventis Pharma Ltd Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) 2001-03-30 2001-05-23 Pfizer Ltd Compounds
BR0209054A (pt) 2001-04-19 2004-04-20 Bayer Ag Arilsulfonamidas como agentes antivirais
RU2003138074A (ru) 2001-06-08 2005-02-20 Цитови Инк. (US) Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение
WO2003000249A1 (en) 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. Function regulator for retinoid relative receptor
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP1622872A1 (en) 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
PL214849B1 (pl) * 2003-09-04 2013-09-30 Wockhardt Ltd Tetrahydrat soli kwasu benzochinolizyno-2-karboksylowego z arginina, sposób jego wytwarzania, kompozycja zawierajaca przedmiotowy tetrahydrat soli oraz jego zastosowanie
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005097096A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
KR20070067165A (ko) 2004-10-13 2007-06-27 피티씨 테라퓨틱스, 인크. 넌센스 변이 억제용 화합물, 및 이의 사용 방법
CA2603402C (en) * 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN101193632A (zh) * 2005-04-08 2008-06-04 Ptc医疗公司 用于无义突变抑制治疗的口服活性1,2,4-噁二唑组合物
IN2014CN04406A (enExample) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
MX2009002439A (es) * 2006-09-08 2009-03-27 Ptc Therapeutics Inc Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
SG185979A1 (en) 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
DK2073805T3 (da) * 2006-10-12 2015-06-15 Ptc Therapeutics Inc Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
ES2436781T3 (es) 2007-12-17 2014-01-07 The Regents Of The University Of Michigan Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
CN101977912A (zh) 2008-03-19 2011-02-16 Osi医药有限公司 mTOR抑制剂的盐形式
CA2729212C (en) 2008-06-24 2014-04-01 Irm Llc Compounds and methods for modulating g protein-coupled receptors
CN103435569B (zh) 2008-07-14 2015-08-19 法罗肯生物科学公司 作为金属螯合剂的脱氮杂去铁硫辛聚醚类似物的新型盐和多晶型物
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
CN106455571A (zh) * 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
AR100771A1 (es) 2014-06-06 2016-11-02 Ptc Therapeutics Inc Métodos de tratamiento que utilizan el ácido 1,2,4-oxadiazolbenzoico

Also Published As

Publication number Publication date
WO2015134711A1 (en) 2015-09-11
JP2020045354A (ja) 2020-03-26
JP2017507158A (ja) 2017-03-16
TWI636978B (zh) 2018-10-01
CA2942147C (en) 2022-12-13
EP3113619A1 (en) 2017-01-11
EA201691789A1 (ru) 2017-02-28
US20170066730A1 (en) 2017-03-09
US10618877B2 (en) 2020-04-14
EA032779B1 (ru) 2019-07-31
KR20230024431A (ko) 2023-02-20
KR20160122268A (ko) 2016-10-21
IL247653A0 (en) 2016-11-30
US20190152931A1 (en) 2019-05-23
CN112979574A (zh) 2021-06-18
JP6946001B2 (ja) 2021-10-06
TWI695717B (zh) 2020-06-11
TW201836605A (zh) 2018-10-16
KR102497273B1 (ko) 2023-02-07
EP3113619A4 (en) 2017-09-13
CA3174516A1 (en) 2015-09-11
US20180179170A1 (en) 2018-06-28
US10233161B2 (en) 2019-03-19
JP2021165299A (ja) 2021-10-14
TW201620883A (zh) 2016-06-16
JP7335795B2 (ja) 2023-08-30
CA2942147A1 (en) 2015-09-11
US9873677B2 (en) 2018-01-23
CN106455571A (zh) 2017-02-22
CN112979575A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
IL247653B (en) Pharmaceutical compositions and benzoic acid salts of 4,2,1-oxadiazole
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL246833A0 (en) New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
IL250882A0 (en) A new pharmaceutical compound containing a hydroxamic acid derivative or a salt thereof
IL252373A0 (en) Hydrobromic acid isoxazole compounds as lpxc inhibitors
IL246447A0 (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
IL246655B (en) A medical preparation containing a pyridyl amino acetic acid compound
ZA201700843B (en) Oral pharmaceutical composition of isotretinoin
DK3200779T3 (en) Novel anthranilic acid derivatives
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
PT3236938T (pt) Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol
IL259073A (en) History of abscisic acid - converted at the 3' position
SI3236950T1 (sl) Farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive soli ali estre in amlodipin ali njegove farmacevtsko sprejemljive soli
HUE038267T2 (hu) Herbicid hatású benzoesav-amid-származékok
SG11201608123VA (en) Pharmaceutical composition for external use
PT3174535T (pt) Formulação nanoparticulada compreendendo um inibidor de mpges-1
SG11201608124XA (en) Pharmaceutical composition for external use
HUP1400520A2 (hu) Gyógyászati készítmény elõállítására alkalmazható laquinimod sók
HUP1400102A2 (hu) Nanostrukturált zanamivirt gyógyszerészetileg elfogadott sóit, gyógyszerészetileg elfogadott észtereit és kokristályait tartalmazó készítmény és eljárás elõállításukra
SG11201608122PA (en) Pharmaceutical composition for external use
TH1601002841A (th) การใช้เกลือของกรดเบนโซอิกในการผลิตองค์ประกอบสำหรับการป้องกันหรือ การบำบัด โรคสมองเสื่อม หรือภาวะสูญเสียความสามารถของสมองเล็กน้อย
HU231256B1 (hu) Nanostrukturált rosuvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra